Search Back New search Go to resultsDiseaseMain groupCross-Sectional, Transplantation, Cellular TherapyHematologic NeoplasmsProtocol groupAcute LeukemiasCellular TherapyDiseaseAcute Lymphoblastic LeukaemiaCAR T-Cell TherapySubgroupB-ALLICD10C91.0-MeSHPrecursor B-Cell Lymphoblastic Leukemia-LymphomaSequenceChemotherapyChemo-substanceCyclophosphamideCytarabineEtoposideFludarabineChemo-substanceCyclophosphamideCytarabineEtoposideFludarabineChemo-substanceCyclophosphamideCytarabineEtoposideFludarabineChemo-substanceCyclophosphamideCytarabineEtoposideFludarabineNo. Substances2 RadiotherapySupportive therapySupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronSupportive substanceBalanced Crystalloid SolutionDexamethasoneGranisetronNo. Substances23Protocol classificationTherapy classificationalternativecurrent standardIntensityStandard doseTherapy indicationseveral possibleTherapy phaseTherapy intentionRisksEmetogenicity (MASCC/ESMO) only studiesPublicationAuthorMaude SLDiseaseB-ALL, CD19+ rezidivierte oder refraktäre B-ALL, Lymphodepletion vor CAR T-Zell TherapieOriginPerelman School of Medicine and Abramson Cancer Center, University of Pennsylvania, ELIANA trialProtocols in Revision 2 protocols foundProtocols under revision.Cytarabine 500 / Etoposide 150, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1832 V1.0)Fludarabine 30 / Cyclophosphamide 500, Acute Lymphoblastic Leukaemia, Lymphodepletion (PID1831 V1.0)
